Cargando…
Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia
OBJECTIVE: This study aimed to investigate the function and mechanism of neddylation of HDAC1 underlying drug resistance of AML cells. METHODS: Evaluation experiments of effects of HDAC1 on drug resistance of AML cells were performed with AML cell transfected with constructs overexpressing HDAC1 or...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664585/ https://www.ncbi.nlm.nih.gov/pubmed/31358016 http://dx.doi.org/10.1186/s12964-019-0393-8 |
_version_ | 1783439915721162752 |
---|---|
author | Lai, Qiu-yu He, Ying-zhi Peng, Xiong-wen Zhou, Xuan Liang, Dan Wang, Liang |
author_facet | Lai, Qiu-yu He, Ying-zhi Peng, Xiong-wen Zhou, Xuan Liang, Dan Wang, Liang |
author_sort | Lai, Qiu-yu |
collection | PubMed |
description | OBJECTIVE: This study aimed to investigate the function and mechanism of neddylation of HDAC1 underlying drug resistance of AML cells. METHODS: Evaluation experiments of effects of HDAC1 on drug resistance of AML cells were performed with AML cell transfected with constructs overexpressing HDAC1 or multi-drug resistance AML cells transfected with siRNA for HDAC1 through observing cell viability, percentage of apoptotic cell, doxorubicin-releasing index and multidrug resistance associated protein 1 (MRP1) expression. Neddylation or ubiquitination of HDAC1 was determined by immunoprecipitation or Ni2(+) pull down assay followed by western blot. The role of HDAC1 was in vivo confirmed by xenograft in mice. RESULTS: HDAC1 was significantly upregulated in refractory AML patients, and in drug-resistant AML cells (HL-60/ADM and K562/A02). Intracellular HDAC1 expression promoted doxorubicin resistance of HL-60, K562, and primary bone marrow cells (BMCs) of remission AML patients as shown by increasing cell viability and doxorubicin-releasing index, inhibiting cell apoptosis. Moreover, HDAC1 protein level in AML cells was regulated by the Nedd8-mediated neddylation and ubiquitination, which further promoted HDAC1 degradation. In vivo, HDAC1 overexpression significantly increased doxorubicin resistance; while HDACs inhibitor Panobinostat markedly improved the inhibitory effect of doxorubicin on tumor growth. Furthermore, HDAC1 silencing by Panobinostat and/or lentivirus mediated RNA interference against HDAC1 effectively reduced doxorubicin resistance, resulting in the inhibition of tumor growth in AML bearing mice. CONCLUSION: Our findings suggested that HDAC1 contributed to the multidrug resistance of AML and its function turnover was regulated, at least in part, by post-translational modifications, including neddylation and ubiquitination. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-019-0393-8) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-6664585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-66645852019-08-05 Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia Lai, Qiu-yu He, Ying-zhi Peng, Xiong-wen Zhou, Xuan Liang, Dan Wang, Liang Cell Commun Signal Research OBJECTIVE: This study aimed to investigate the function and mechanism of neddylation of HDAC1 underlying drug resistance of AML cells. METHODS: Evaluation experiments of effects of HDAC1 on drug resistance of AML cells were performed with AML cell transfected with constructs overexpressing HDAC1 or multi-drug resistance AML cells transfected with siRNA for HDAC1 through observing cell viability, percentage of apoptotic cell, doxorubicin-releasing index and multidrug resistance associated protein 1 (MRP1) expression. Neddylation or ubiquitination of HDAC1 was determined by immunoprecipitation or Ni2(+) pull down assay followed by western blot. The role of HDAC1 was in vivo confirmed by xenograft in mice. RESULTS: HDAC1 was significantly upregulated in refractory AML patients, and in drug-resistant AML cells (HL-60/ADM and K562/A02). Intracellular HDAC1 expression promoted doxorubicin resistance of HL-60, K562, and primary bone marrow cells (BMCs) of remission AML patients as shown by increasing cell viability and doxorubicin-releasing index, inhibiting cell apoptosis. Moreover, HDAC1 protein level in AML cells was regulated by the Nedd8-mediated neddylation and ubiquitination, which further promoted HDAC1 degradation. In vivo, HDAC1 overexpression significantly increased doxorubicin resistance; while HDACs inhibitor Panobinostat markedly improved the inhibitory effect of doxorubicin on tumor growth. Furthermore, HDAC1 silencing by Panobinostat and/or lentivirus mediated RNA interference against HDAC1 effectively reduced doxorubicin resistance, resulting in the inhibition of tumor growth in AML bearing mice. CONCLUSION: Our findings suggested that HDAC1 contributed to the multidrug resistance of AML and its function turnover was regulated, at least in part, by post-translational modifications, including neddylation and ubiquitination. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12964-019-0393-8) contains supplementary material, which is available to authorized users. BioMed Central 2019-07-29 /pmc/articles/PMC6664585/ /pubmed/31358016 http://dx.doi.org/10.1186/s12964-019-0393-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Lai, Qiu-yu He, Ying-zhi Peng, Xiong-wen Zhou, Xuan Liang, Dan Wang, Liang Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
title | Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
title_full | Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
title_fullStr | Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
title_full_unstemmed | Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
title_short | Histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
title_sort | histone deacetylase 1 induced by neddylation inhibition contributes to drug resistance in acute myelogenous leukemia |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6664585/ https://www.ncbi.nlm.nih.gov/pubmed/31358016 http://dx.doi.org/10.1186/s12964-019-0393-8 |
work_keys_str_mv | AT laiqiuyu histonedeacetylase1inducedbyneddylationinhibitioncontributestodrugresistanceinacutemyelogenousleukemia AT heyingzhi histonedeacetylase1inducedbyneddylationinhibitioncontributestodrugresistanceinacutemyelogenousleukemia AT pengxiongwen histonedeacetylase1inducedbyneddylationinhibitioncontributestodrugresistanceinacutemyelogenousleukemia AT zhouxuan histonedeacetylase1inducedbyneddylationinhibitioncontributestodrugresistanceinacutemyelogenousleukemia AT liangdan histonedeacetylase1inducedbyneddylationinhibitioncontributestodrugresistanceinacutemyelogenousleukemia AT wangliang histonedeacetylase1inducedbyneddylationinhibitioncontributestodrugresistanceinacutemyelogenousleukemia |